The PATHO-GENE® HPV type 16/18/31/33/51 probe is a mixture of biotin-labeled HPV-16, HPV- 18, HPV-31, HPV-33 and HPV-51 specific probes in buffered formamide and hybridization enhancers.
Product Details
Application Notes:
The PATHO-GENE® HPV type 16/18/31/33/51 probe employs a mixture of the HPV-16, HPV -18, HPV-31, HPV-33 and HPV-51 specific probes that detect HPV types that have been associated with either condyloma or cervical intraepithelial neoplasia (CIN) and carcinoma in situ (CIS). The probe mixture is denatured and hybridized to the tissue section fixed and pretreated on the microscope slide. Specific hybridization between the HPV DNA probe and DNA in the specimen is determined by the detection of biotin.
Shipping:
Blue Ice
Long Term Storage:
+4°C
Use/Stability:
Stable for at least one year after receipt when stored as recommended. Following dilution in appropriate buffer system, product is stable for at least 2 days.
Handling:
Allow contents to warm up to room temperature prior to use.
Technical Info/Product Notes:
HPV probe can be optimized for polymer detection system using diluent buffer, In situ hybridization buffer for HPV probes (Ready-to-Use) (Prod. No. ENZ-33905).
This product or the use of this product is covered by one or more Enzo patents, including, but not limited to the following: U.S. Patent No. 4,994,373; Canadian Patent No. 1,309,672; and patents pending.
Regulatory Status:
RUO - Research Use Only
Negative detection of HPV 16/18/31/33/51 with ENZ-32882 PATHO-GENE® HPV 16/18/31/33/51 probes in vulva FFPE tissue.
Positive detection of HPV 16/18/31/33/51 with ENZ-32882 PATHO-GENE® HPV 16/18/31/33/51 probes in HPV infected cervical FFPE tissue.
Please mouse over
Product Literature References
Penile squamous cell carcinoma exclusive to the shaft, with a proposal for a novel staging system: B. Tekin, et al.; Human Pathol. 134, 92 (2023), Abstract;
CEA as a blood-based biomarker in anal cancer: R. Hester, et al.; Oncotarget 12, 1037 (2021), Abstract; Full Text
A proportion of primary squamous cell carcinomas of the parotid gland harbor high risk human papillomavirus: B. Xu, et al.; Histopathology 69, 921 (2016), Abstract;
RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization: L.M. Rooper, et al.; Oral Oncol. 55, 11 (2016), Application(s): Evaluation for HPV DNA was performed, Abstract;
The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma: B. Xu, et al.; Hum. Pathol. 54, 193 (2016), Abstract;
